Skip to main content
Clinical Trials/NL-OMON39800
NL-OMON39800
Completed
Phase 4

Prospective, randomized, open label trial of six vs. twelve months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction. - DAPT-STEMI

Maasstadziekenhuis0 sites580 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
DAPT treatment after PCI
Sponsor
Maasstadziekenhuis
Enrollment
580
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
July 1, 2017
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Maasstadziekenhuis

Eligibility Criteria

Inclusion Criteria

  • STEMI patients between 18\-85 years, who underwent PCI with second generation DES implantation

Exclusion Criteria

  • Key Exclusion Criteria Enrollment: Intolerance to Aspirin, Plasugrel, Ticagrelor, Heparin, Bivaluridin, Everoliumus or Zotarolimus.
  • Known bleeding diathesis or known coagulopathy.
  • Planned elective surgical procedure necessitating interruption of dual antiplatelet therapy during the first 6 months after randomization.;Key Exclusion Criteria Randomization:
  • Occurrence of death, myocardial infarction, stent thrombosis and target vessel or lesion revascularization during the first 6 months after inclusion.
  • Stroke or bleeding requiring discontinuation of DAPT during the first 6 months after inclusion.
  • Oral anticoagulant therapy with coumarin derivates.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
A randomized, open-label, parallel-group, multi-center study of adding edoxaban or clopidogrel to aspirin to maintain patency in subjects with peripheral arterial disease following femoropopliteal endovascular intervention-edoxaban in peripheral arterial disease (ePAD)narrowing of the peripheral arteries (mostly in the legs)periferal arterial disease10003216
NL-OMON40071Daiichi Sankyo Development Ltd14
Completed
Phase 4
A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitisAutoimmune hepatitis1001965410003816
NL-OMON52983eids Universitair Medisch Centrum66
Completed
Phase 3
A randomised, open-label clinical trial assessing the efficacy of octreotide to decrease iron infusion and blood transfusion requirements in patients with refractory anaemia due to gastrointestinal bleeding from angiodysplasias.angiodysplasiavascular malformation10017959
NL-OMON44271Maag-, darm- en leverziekten62
Completed
Not Applicable
An open-label, adaptive multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of RO7234292 in csf and plasma, and safety and tolerability following intrathecal administration in patients with Huntington's disease.Chronic Progressive Choreadegenerative chorea1002929910029317
NL-OMON49037Hoffmann-La Roche4
Completed
Phase 2
A randomised, controlled, double-blind trial to investigate the effects of a new infant formula on growth, tolerance and safety in healthy term infants.effect op de groei van zuigelingeneffects on growth
NL-OMON39783utricia Research - Centre for Specialised Nutrition121